The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer - PubMed (original) (raw)
The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer
B M Cantwell et al. Eur J Cancer Clin Oncol. 1988 Feb.
Abstract
Eight-eight previously untreated patients with small cell lung cancer were treated with a combination of VP16, adriamycin and vincristine (VPAV) for three courses. Resistance to these drugs is associated with the multidrug resistance (MDR) membrane glycoprotein in cell lines in vitro. The clinical relevance of this mechanism of resistance was assessed by using a second line treatment with intravenous infusions of ifosfamide/mesna 5 g/m2 every 3 weeks in patients with only partial responses or non-responders. Cross-resistance to alkylating agents is rare in the MDR. Ifosfamide produced partial responses in six (43%) of 14 patients unresponsive to prior therapy. Intravenously infused ifosfamide/mesna was also used in consolidation therapy with only minor bone marrow or urinary tract toxicity. This did not prevent CNS relapse. The overall response rate to VPAV was 69% and for all treatment modalities, 75%. Median survival for all patients ws 39.5 weeks and 59 weeks for all patients attaining complete response. The addition of large fraction chest irradiation given with the final course of induction chemotherapy to those with good chemotherapy responses produced a further response in 44% of assessable patients. Combined modality treatment resulted in moderate and reversible toxicity. The lack of improved survival with ifosfamide and the resistance of the majority of patients to salvage with ifosfamide/mesna suggested that the MDR is not the major mechanism of resistance in the clinic, since cross-resistance to alkylating agents of this type is not a feature of MDR cells.
Similar articles
- Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).
Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH; Eastern Cooperative Oncology Group. Ettinger DS, et al. Lung Cancer. 2002 Sep;37(3):311-8. doi: 10.1016/s0169-5002(02)00074-0. Lung Cancer. 2002. PMID: 12234701 Clinical Trial. - Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S, et al. Wolf M, et al. J Clin Oncol. 1987 Dec;5(12):1880-9. doi: 10.1200/JCO.1987.5.12.1880. J Clin Oncol. 1987. PMID: 2824710 Clinical Trial. - Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group.
Postmus PE, Smit EF, Kirkpatrick A, Splinter TA. Postmus PE, et al. Eur J Cancer. 1993;29A(2):204-7. doi: 10.1016/0959-8049(93)90176-g. Eur J Cancer. 1993. PMID: 8380697 Clinical Trial. - Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
Cited by
- Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.
Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. Allen JW, et al. J Clin Oncol. 2014 Aug 10;32(23):2463-70. doi: 10.1200/JCO.2013.51.4109. Epub 2014 Jul 7. J Clin Oncol. 2014. PMID: 25002722 Free PMC article. Clinical Trial. - Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A, Cerchietti L. Clozel T, et al. Cancer Discov. 2013 Sep;3(9):1002-19. doi: 10.1158/2159-8290.CD-13-0117. Epub 2013 Aug 16. Cancer Discov. 2013. PMID: 23955273 Free PMC article. Clinical Trial. - Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.
Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL. Millward MJ, et al. Br J Cancer. 1993 May;67(5):1031-5. doi: 10.1038/bjc.1993.189. Br J Cancer. 1993. PMID: 8388231 Free PMC article. Clinical Trial. - Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB, Christensen IJ, Sehested M, Hansen HH, Vindeløv L. Jensen PB, et al. Br J Cancer. 1993 Feb;67(2):311-20. doi: 10.1038/bjc.1993.58. Br J Cancer. 1993. PMID: 8094293 Free PMC article. - Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker GL, Faulds D. Plosker GL, et al. Drugs. 1993 May;45(5):788-856. doi: 10.2165/00003495-199345050-00011. Drugs. 1993. PMID: 7686469 Review.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Medical